The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price increased by equities researchers at Barclays from ...

$VIR insiders have traded $VIR stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales. Here’s a ...

Brent Sabatini, the SVP of $VIR, sold 1,562 shares of the company on 02-13-2025 for an estimated $14,291. We received data on the trade from a recent SEC filing. This ...

Short interest in Vir Biotechnology Inc (NASDAQ ... this short interest to close out their positions without sending the stock sharply higher.

Barclays analyst Gena Wang raised the firm’s price target on Vir Biotechnology (VIR) to $31 from $26 and keeps an Overweight rating on the ...